{"schema_version":"secwatch.filing_event.v1","accession":"0001493152-24-010152","form_type":"8-K","ticker":"BFRI","cik":"0001858685","company_name":"Biofrontera Inc.","filed_at":"2024-03-15T23:59:59+00:00","discovered_at":"2026-05-14T18:03:26.109185+00:00","generated_at":"2026-06-04T17:58:49.332563+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Biofrontera reports record FY2023 revenue of $34.1M, +19% YoY; Q4 net income $3.5M","bullets":["FY2023 total revenues $34.1M (+19% YoY); operating expenses $56.7M (incl $2M one-time legal).","Q4 2023 revenue $10.6M (+4% YoY); net income $3.5M ($1.65/shr) vs loss $2.8M ($2.16 loss/shr) in Q4 2022.","Adjusted EBITDA for Q4 negative $3.2M (improved from negative $4.4M in prior year).","Submitted sNDA to increase Ameluz use to 3 tubes for AK; PDUFA Oct 4, 2024. Phase 3 enrollment for sBCC completed.","Restructured LSA to cut transfer price to 25% for 2024-2025; acquired patents for new portable PDT lamp."],"urls":{"canonical":"https://secwatch.observer/filing/0001493152-24-010152","json":"https://secwatch.observer/filing/0001493152-24-010152.json","markdown":"https://secwatch.observer/filing/0001493152-24-010152.md","text":"https://secwatch.observer/filing/0001493152-24-010152.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1858685/000149315224010152/0001493152-24-010152-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1858685/000149315224010152/form8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-04T17:58:49.332563+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"251983b2b10ae5ac83d82713eb5f15ff8837004c","claim":"Biofrontera Inc. reported the fourth quarter of 2023 results: revenue $10.6 million, net income $3.5 million, EPS $1.65 per share.","evidence_excerpt":"Total revenues for the fourth quarter of 2023 were $10.6 million, an increase of $0.5 million, or ~4%, compared with $10.1 million for the fourth quarter of 2022.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1858685/000149315224010152/0001493152-24-010152-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the fourth quarter of 2023"},{"label":"Revenue","value":"$10.6 million"},{"label":"Net income","value":"$3.5 million"},{"label":"EPS","value":"$1.65 per share"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"},{"claim_id":"409a0248ce22cf2f13dcd0d402e22f9baac32a30","claim":"Biofrontera Inc. reported financial results for the three and twelve months ended December 31, 2023.","evidence_excerpt":"On March 15, 2024, Biofrontera Inc. (the “Company”) issued a press release announcing its financial and operational results for the fourth quarter and fiscal year ended December 31, 2023.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1858685/000149315224010152/0001493152-24-010152-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the three and twelve months ended December 31, 2023"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}